Last C$7.65 CAD
Change Today +0.23 / 3.10%
Volume 15.6K
RX On Other Exchanges
As of 9:45 AM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

biosyent inc (RX) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/9/14 - C$8.19
52 Week Low
07/31/13 - C$1.45
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOSYENT INC (RX)

Related News

No related news articles were found.

biosyent inc (RX) Related Businessweek News

No Related Businessweek News Found

biosyent inc (RX) Details

BioSyent Inc., a life science company, engages in the marketing of pharmaceutical products in Canada. It is also involved in manufacturing and marketing non-chemical bio and health-friendly insecticides worldwide. The company markets FeraMAX 150, an oral hematinic for the prevention and treatment of iron deficiency anaemia; and FeraMAX Powder, an oral iron supplement. It also offers Cathejell Jelly 2% indicated for surface anesthesia and lubrication for various procedures, including male and female cystoscopies, catheterizations, and other endourethral operations; endoscopies, proctoscopies, and rectoscopies; and tracheal intubations, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis. In addition, BioSyent Inc. manufactures and markets Protect-It, a non-chemical, food-safe grain insecticide used as a preventative treatment against insect infestations in stored grains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 1947 and is headquartered in Toronto, Canada.

Founded in 1947

biosyent inc (RX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: C$200.7K
Chief Financial Officer and Vice President
Total Annual Compensation: C$126.6K
Vice President of Biosyent Pharma Inc.
Total Annual Compensation: C$120.8K
Compensation as of Fiscal Year 2013.

biosyent inc (RX) Key Developments

BioSyent Inc. Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-18-2014 04:30 PM

BioSyent Inc. Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-18-2014 04:30 PM. Venue: Toronto Board of Trade, 1 First Canadian Place (Corner of Bay and Adelaide), Toronto, ON M5X 1C1, Canada.

BioSyent Inc. Reports Earnings Results for the First Quarter Ended March 31, 2014

BioSyent Inc. reported earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported revenue of CAD 2,448,101 compared to CAD 1,541,843 million for the same period a year ago. Profit before tax was CAD 687,672 compared to CAD 481,963 for the same period a year ago. Profit after tax was CAD 511,421 compared to CAD 344,410 for the same period a year ago. Diluted EPS was CAD 0.04 compared to CAD 0.02 in first quarter of 2013.

BioSyent Inc., Annual General Meeting, Jun 10, 2014

BioSyent Inc., Annual General Meeting, Jun 10, 2014., at 09:00 US Eastern Standard Time. Location: The Sheraton Toronto Airport Hotel & Conference Centre (Niagara Room). Agenda: To receive the audited financial statements for the fiscal year ended December 31, 2013, together with the auditors' report thereon; to elect directors for the ensuing year; to appoint auditors for the ensuing year and to authorize the directors to fix the remuneration to be paid to the auditors; to consider and, if thought appropriate, approve the Company's new ‘10% rolling’ incentive stock option plan in the form attached as Schedule ‘B’ to the accompanying information circular; and to transact such other business as may properly be transacted at such meeting or at any adjournment thereof.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RX:CN C$7.60 CAD +0.18

RX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RX.
View Industry Companies

Industry Analysis


Industry Average

Valuation RX Industry Range
Price/Earnings 47.1x
Price/Sales 10.7x
Price/Book 17.3x
Price/Cash Flow 45.2x
TEV/Sales 10.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOSYENT INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at